Compare Dyne Therapeutics Inc. Common Stock (DYN) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs NetFlix Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.29 (market cap $2.81B), while NetFlix Inc trades at $72.4 (market cap $293.85B). The key difference: NetFlix Inc is far larger — about 104.6× Dyne Therapeutics Inc. Common Stock's market cap, and NetFlix Inc is more actively traded (39,920,482 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and NetFlix Inc for 126 Days on average.
| DYN | NFLX | |
|---|---|---|
Market Cap | $2.81B | $293.85B |
Volume | 2,195,902 | 39,920,482 |
Sector | Health | Media |
52-Week High | $26.78 | $124.13 |
52-Week Low | $14.60 | $67.06 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $2.13B | $299.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Netflix (NFLX) trades at $70.48, down 0.18% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals with Q2 2026 EPS of $0.80 beating expectations, revenue of $45.18B in 2025, and a net income margin of 28.22%. Recent news highlights strategic moves into live sports and content expansion, while analyst consensus remains bullish with a $89.39 price target.
The outlook for NFLX is positive due to robust earnings growth and expanding profitability, but risks include competitive pressures and market volatility. The stock offers potential upside based on analyst targets, supported by strong cash flow and institutional interest, though investors should monitor execution on live content initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
